Search research articles
Contact Us
Filters
Showing results (141-150 of 154) with videos related to
Page
of 16
Sort By:
ESMO Open
|
April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
C Marchetti, A Fagotti, R Fruscio, et al.
Gynecologic Oncology
|
September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
Mansoor R Mirza, B Benigno, A Dørum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
M K Wilson, E Pujade-Lauraine, D Aoki, et al.
ESMO Open
|
May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response
C Marchetti, A Fagotti, R Fruscio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
M C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open
|
May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib
L Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
S Pignata, D Califano, D Lorusso, et al.
ESMO Open
|
September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
E D Capoluongo, B Pellegrino, L Arenare, et al.
ESMO Open
|
January 25, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer
S Koppikar, A Oaknin, K Govind Babu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I Ray-Coquard, A Leary, S Pignata, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 154) with videos related to
Sort By:
Page
of 16
ESMO Open
|
April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
C Marchetti, A Fagotti, R Fruscio, et al.
Gynecologic Oncology
|
September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
Mansoor R Mirza, B Benigno, A Dørum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 21, 2016
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease
M K Wilson, E Pujade-Lauraine, D Aoki, et al.
ESMO Open
|
May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response
C Marchetti, A Fagotti, R Fruscio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2018
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer
M C Piccirillo, G Scambia, A Bologna, et al.
ESMO Open
|
May 20, 2025
HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib
L Beltrame, L Mannarino, A Sergi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2024
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
S Pignata, D Califano, D Lorusso, et al.
ESMO Open
|
September 26, 2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
E D Capoluongo, B Pellegrino, L Arenare, et al.
ESMO Open
|
January 25, 2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer
S Koppikar, A Oaknin, K Govind Babu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 21, 2023
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
I Ray-Coquard, A Leary, S Pignata, et al.
Page
of 16